Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2023-04-25 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
关于续聘2023年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement by Meikang Biotechnology Co., Ltd. regarding the reappointment of the audit firm for the fiscal year 2023. It details the qualifications, past performance, and independence of the audit firm (Lixin Certified Public Accountants), the audit fees, and the approval process by the board and independent directors. The document does not contain any actual audit report or financial statements but is a formal notice about the continuation of the audit engagement subject to shareholder approval. This fits the category of an Audit Report / Information announcement related to audit firm appointment rather than the audit report itself or an annual report. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2023
2023-04-25 Chinese
中天国富证券有限公司关于美康生物科技股份有限公司2022年度募集资金存放与实际使用情况核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Zhongtian Guofu Securities Co., Ltd. regarding the 2022 annual special verification opinion on the deposit and actual use of raised funds by Meikang Biotechnology Co., Ltd. It includes extensive information on the amount of funds raised, their usage, management, investment projects, and compliance with regulatory requirements. The document references regulatory guidelines and includes an auditor's verification opinion and sponsor institution's verification opinion. The content focuses on the management and use of funds raised through a specific stock issuance, with detailed financial figures and project progress. This matches the characteristics of an Audit Report / Information (AR) as it is a standalone audit-related report on the use of raised funds, not a full annual report or earnings release. The document length (9626 characters) and detailed financial and compliance content support this classification. FY 2022
2023-04-25 Chinese
2022年度独立董事述职报告（田云鹏）
Board/Management Information Classification · 95% confidence The document is titled as the "2022年度独立董事述职报告" which translates to "2022 Annual Independent Director's Work Report." It is a detailed report by an independent director about their attendance, opinions, committee work, investigations, investor protection efforts, training, and other duties during the year 2022. The content focuses on governance, oversight, and the independent director's role rather than financial results or audit opinions. It does not contain financial statements or earnings data, nor is it an announcement or proxy material. This type of document fits best under Board/Management Information (MANG) as it relates to board members' activities and governance roles.
2023-04-25 Chinese
未来三年（2023-2025年）股东回报规划
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from 美康生物科技股份有限公司 regarding its shareholder return plan for the years 2023-2025. It outlines the company's dividend policy, conditions for cash dividends, decision-making procedures, and mechanisms for shareholder returns. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and it is dated April 24, 2023. The content focuses on the company's planned approach to profit distribution and shareholder returns rather than presenting financial statements or audit results. The document length is 3786 characters, which is relatively short and more consistent with an announcement or policy statement rather than a full financial report. It does not contain actual financial data or results but rather a policy framework and procedural details. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the company's dividend policy and shareholder return plan, not a full report like an Annual Report or Earnings Release.
2023-04-25 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 美康生物科技股份有限公司 regarding changes in accounting policies. It details the reasons for the changes, references specific accounting standards and interpretations issued by the Ministry of Finance, and explains the impact and approval process of these changes. The document is relatively short (3631 characters) and does not contain actual financial statements or detailed financial data. Instead, it serves as a formal disclosure of the accounting policy changes approved by the board and supervisory committee. This type of document is best classified as a Regulatory Filing (RNS) because it is an official announcement about accounting policy changes without the full financial report or audit details.
2023-04-25 Chinese
中天国富证券有限公司关于美康生物科技股份有限公司2022年度持续督导跟踪报告
Regulatory Filings
2023-04-25 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.